Faculty Profiles - NAKATSUKA Mikiya

MISC - NAKATSUKA Mikiya

Division display 521 - 540 of about 617 ／ All the affair displays >>

性同一性障害：「生」と「性」の正しい理解の輪を広げよう

中塚幹也

全国助産師協議会ニュースレター巻頭 2004

Impaired vascular function in women with recurrent pregnancy loss: Involvement of antiphospholipid antibodies.

Nakatsuka M, Noguchi S, Kamada Y, Sasaki A, C.Chekir, H.Lin, Hiramatsu Y

IX international congress of reproductive immunology -I SIR- ,,97-100 2004

抗リン脂質抗体陽性不育症症例における血清Thrombomodulin値と産科的予後.

中塚幹也, 鎌田泰彦, 野口聡一, 佐々木愛子, Chebib Chekir, 平松祐司

産婦人科の実際 2004

胎児発育から見た妊娠中毒症の胎盤病理所見：定量化の試み.

Chebib CHEKIR, 中塚幹也, 野口聡一, 鎌田泰彦, 佐々木愛子, HAO Lin, 平松祐司

日本妊娠高血圧学会雑誌 2004

不育症の病態別にみた子宮動脈血管抵抗および凝固関連マーカーの妊娠経過による変化.

中塚幹也, 小西秀樹, 鎌田泰彦, Chebib Chekir, 羽原俊宏, 野口聡一, 工藤尚文

産婦人科の実際 2004

Advanced glycation end products induce secretion of chemokines and apoptosis in human first trimester trophoblasts.

Konishi H, Nakatsuka M, Chekir C, Noguchi S, Kamada Y, Sasaki A, Hiramatsu Y

Human Reproduction 2004

思春期の性同一性障害症例の社会的，精神的，身体的問題点と医学的介入の可能性についての検討

中塚幹也, 江見弥生

母性衛生 2004

思春期の性同一性障害症例の社会的，精神的，身体的問題点と医学的介入の可能性についての検討.

中塚幹也, 江見弥生

母性衛生 2004

「子宮頚癌・子宮体癌・卵巣癌の診断と治療-最近の研究動向-」癌登録の歴史と実際

奥田博之, 中塚幹也

日本臨床 2004増刊 2004

抗リン脂質抗体陽性不育症症例における血清Thrombomodulin値と産科的予後

中塚幹也, 鎌田泰彦, 野口聡一, 佐々木愛子, Chebib Chekir, 平松祐司

産婦人科の実際 2004

子宮内膜症診療におけるColor Doppler検査の有用性の検討.

安達美和, 中塚幹也, 松尾環, 野口聡一, 佐々木愛子, Chekir Chebib, 鎌田泰彦, 平松祐司

エンドメトリオーシス研究会会誌 2004

子宮腺筋症正所性・異所性子宮内膜におけるユビキチン化蛋白に関する検討.

鎌田泰彦, 中塚幹也, 野口聡一, Chekir Chebib, 佐々木愛子, 平松祐司

エンドメトリオーシス研究会会誌 2004

ヘパリン療法を施行した不育症妊婦における骨代謝の検討.

野口聡一, 中塚幹也, 鎌田泰彦, 佐々木愛子, 平松祐司, 大井伸子

Osteoporosis Japan 2004

33-4.多嚢胞性卵巣症候群症例における子宮動脈血管抵抗の検討(第162群思春期・更年期・老年期4)(一般演題)

佐々木愛子, 中塚幹也, シェキルシェビブ, 野口聡一, 鎌田泰彦, 平松祐司

日本産科婦人科學會雜誌 56 ( 2 ) 709 - 709 2004

24-15.正常子宮内膜および子宮腺筋症内膜でのユビキチン化蛋白の存在様式に関する検討(第116群子宮内膜症・腺筋症4)(一般演題)

鎌田泰彦, 中塚幹也, 野口聡一, シュキルシュビブ, 佐々木愛子, 平松祐司

日本産科婦人科學會雜誌 56 ( 2 ) 612 - 612 2004

24-27.子宮内膜症症例におけるGnRH agonistによる子宮動脈血流改善効果について(第118群子宮内膜症・腺筋症6)(一般演題)

安達美和, 中塚幹也, 松尾環, 佐々木愛子, シュキルシュビブ, 鎌田泰彦, 野口聡一, 平松祐司

日本産科婦人科學會雜誌 56 ( 2 ) 616 - 616 2004

9-11.習慣性流産・不育症妊婦に対するヘパリン療法による骨代謝の変化 : 正常妊婦との比較(第38群不妊・不育2)(一般演題)

野口聡一, 中塚幹也, 鎌田泰彦, 佐々木愛子, シェビブシェキル, 平松祐司

日本産科婦人科學會雜誌 56 ( 2 ) 433 - 433 2004

Nafamostat mesilate suppresses NF-kappa B activation and NO overproduction in LPS-treated macrophages

S Noguchi, M Nakatsuka, H Konishi, Y Kamada, C Chekir, T Kudo

INTERNATIONAL IMMUNOPHARMACOLOGY 3 ( 9 ) 1335 - 1344 2003.9

Language：English Publisher：ELSEVIER SCIENCE BV

Nafamostat mesilate (NM), a clinically used serine protease inhibitor, Suppressed the overproduction of nitric oxide (NO) and the expression of inducible nitric oxide synthase (iNOS) in RAW264.7 murine macrophages treated with lipopolysaccharide (LPS, 100 ng/ml); however, it had little effect oil endothelial NOS (eNOS) in human umbilical vein endothelial cells (HUVEC). Electrophoretic mobility shift assay (EMSA) revealed that LPS activated nuclear factor-kappaB (NF-kappaB) in RAW264.7 cells and that this activation was suppressed by nafamostat mesilate. Western blotting showed that nafamostat mesilate suppressed the phosphorylation and degradation of inhibitor kappaB-alpha (IkappaB-alpha), which holds NF-kappaB in the cytoplasm in an inactivated state. Our observations suggest that nafamostat mesilate is a candidate agent for various diseases such as ischemia-reperfusion, graft rejection, inflammatory diseases, and autoimmune diseases, in which iNOS and/or NF-kappaB are upregulated. (C) 2003 Elsevier B.V. All rights reserved.

DOI： 10.1016/S1567-5769(03)00146-2

Web of Science

researchmap

Nafamostat mesilate suppresses NF-kappa B activation and NO overproduction in LPS-treated macrophages

S Noguchi, M Nakatsuka, H Konishi, Y Kamada, C Chekir, T Kudo

INTERNATIONAL IMMUNOPHARMACOLOGY 3 ( 9 ) 1335 - 1344 2003.9

Language：English Publisher：ELSEVIER SCIENCE BV

DOI： 10.1016/S1567-5769(03)00146-2

Web of Science

researchmap

Increased plasma adrenomedullin in women with recurrent pregnancy loss

M Nakatsuka, T Habara, S Noguchi, H Konishi, T Kudo

OBSTETRICS AND GYNECOLOGY 102 ( 2 ) 319 - 324 2003.8

Language：English Publisher：ELSEVIER SCIENCE INC

OBJECTIVE: To evaluate vascular changes and uterine perfusion in women with recurrent pregnancy loss.
METHODS: We measured plasma levels of adrenomedullin of 100 pregnant women in the midluteal phase of a nonpregnant cycle (control group: n = 62; recurrent pregnancy loss group: n = 38). We measured the pulsatility index (PI) in the uterine arteries by transvaginal pulsed Doppler ultrasonography at the same time.
RESULTS: The plasma level of adrenomedullin in women with recurrent pregnancy loss (5.6 +/- 1.9, mean +/- standard deviation) was significantly higher (P >.001) than that in control women (3.6 +/- 1.7). Uterine arterial PI of women with recurrent pregnancy loss (2.70 +/- 0.47) was significantly higher (P >.001) than that in control women (2.09 +/- 0.39). Plasma level of adrenomedullin had a significant positive correlation with uterine arterial PI both in the control group (r =.58, P <.001) and in the recurrent pregnancy loss group (r =.78, P <.001). Both plasma adrenomedullin concentration (7.2 +/- 2.3) and uterine arterial PI (3.06 +/- 0.36) were significantly high in women with antiphospholipid antibodies.
CONCLUSION: Plasma adrenomedullin may serve as a useful biochemical marker for recurrent pregnancy loss caused by impaired uterine perfusion.

DOI： 10.1016/S0029-7844(03)00481-2

Web of Science

researchmap

　 PREV - NEXT 　

< NAKATSUKA Mikiya >

MISC - NAKATSUKA Mikiya